In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

BioSTAR PFO closure device: NMT Medical launches its BioSTAR bioabsorbable atrial implant July 25 in Canada and Europe. The firm believes there may be a connection between closing septal heart defects, such as patent foramen ovale, with the device and prevention of embolic stroke and transient ischemic attack. NMT Medical estimates the market size in Canada and Europe for the indications to be 250,000 annually. AGA Medical's non-bioabsorbable Amplatzer PFO closure device is also available outside the United States. Both firms have U.S. trials underway to gain stroke prevention indications, and trials in the United States and internationally for prevention of migraine...

You may also be interested in...

With Limited Near-Term PFO Closure Prospects In U.S., NMT Looks To Europe

NMT Medical is banking on strong market growth in Europe to counteract stagnant U.S. performance

Recordati Raises Forecast for Isturisa After Smooth Launches

The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts